Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05028374 · OUTCOME

Observed Response Rate of Anti-SARS-CoV2 Antibody Seroconversion.

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
28 days (+/- 3 days) following a booster dose of the Moderna mRNA COVID-19 vaccine

What was measured

Anti-SARS-CoV2 IgG antibody seroconversion from negative to positive.

Analysis population: Participants who received a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly.

Groups in this outcome

Cohort 1

Multiple myeloma and amyloidosis patients who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.

Cohort 2

Patients with other hematologic malignancies who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.

Cohort 3

Patients with multiple myeloma, amyloidosis, or other hematologic malignancy who had a "weak positive" response to prior COVID-19 vaccine, defined as an anti-spike antibody titer of 1-2 S/CO.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 152
Cohort 250
Cohort 316

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 129Not reportedNot reportedNot reportedNot reported
Cohort 228Not reportedNot reportedNot reportedNot reported
Cohort 30Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        29
      2. group Id
        OG001
        value
        28
      3. group Id
        OG002
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    2. group Id
      OG001
      value
      50
    3. group Id
      OG002
      value
      16
    units
    Participants
description
Anti-SARS-CoV2 IgG antibody seroconversion from negative to positive.
groups
  1. description
    Multiple myeloma and amyloidosis patients who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.
    id
    OG000
    title
    Cohort 1
  2. description
    Patients with other hematologic malignancies who did not develop an anti-spike antibody titer of \>1 S/CO after prior COVID-19 vaccination.
    id
    OG001
    title
    Cohort 2
  3. description
    Patients with multiple myeloma, amyloidosis, or other hematologic malignancy who had a "weak positive" response to prior COVID-19 vaccine, defined as an anti-spike antibody titer of 1-2 S/CO.
    id
    OG002
    title
    Cohort 3
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who received a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly.
reporting Status
POSTED
time Frame
28 days (+/- 3 days) following a booster dose of the Moderna mRNA COVID-19 vaccine
title
Observed Response Rate of Anti-SARS-CoV2 Antibody Seroconversion.
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice